The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass

Background The sivelestat is a neutrophil elastase inhibitor thought to have an effect against acute lung injury (ALI) in patients after scheduled cardiac surgery. However, the beneficial effect of sivelestat in patients undergoing emergent cardiovascular surgery remains unclear. We aim to evaluate the effect of sivelestat on pulmonary protection in patients with ALI after emergent cardiovascular surgery. Methods Firstly, a case-control study in 665 patients undergoing emergent cardiovascular surgery from January 1st, 2020 to October 26th, 2022 was performed. 52 patients who received sivelestat (0.2mg/kg/h for 3 days) and 613 age- and sex-matched controls. Secondly, a propensity-score matched cohort (sivelestat vs control: 50 vs 50) was performed in these 665 patients. The primary outcome was a composite of adverse outcomes, including 30-day mortality, ECMO, continuous renal replacement therapy (CRRT) and IABP, etc. The secondary outcome included pneumonia, ventricular arrhythmias and mechanical ventilation time, etc. Results In propensity-matched patients, the 30-day mortality (16% vs 24%, P=0.32), stroke (2% vs 8%, P=0.17), ECMO(6% vs 10%, P=0.46), IABP(4% vs 8%, P=0.40) and CRRT(8% vs 20%, P=0.08) had no differences between sivelestat and control group; sivelestat could significantly decrease pneumonia (40% vs 62%, P=0.03), mechanical ventilation time (median: 96hours, IQR:72-120hours vs median:148hours, IQR:110-186hours, P<0.01), bilateral pulmonary infiltrates (P<0.01), oxygen index (P<0.01), interleukin-6(P=0.02), procalcitonin(P<0.01) and C-reactive protein(P<0.01). Conclusion Administration of sivelestat might improve postoperative outcomes in patients with ALI after emergent cardiovascular surgery. Our results show that sivelestat may be considered to protect pulmonary function against inflammatory injury by CPB. Registration http://www.chictr.org.cn/showproj.aspx?proj=166643, identifier ChiCTR2200059102.

[1]  Hong-jia Zhang,et al.  Prognostic Impact of Systemic Coagulation-Inflammation Index in Acute Type A Aortic Dissection Surgery , 2022, JACC. Asia.

[2]  Tuo Pan,et al.  Evaluation of low-dose colchicine in patients with cardiopulmonary bypass: study protocol for a randomised controlled trial , 2022, BMJ Open.

[3]  S. Solomon,et al.  Ultrasound imaging of congestion in heart failure: examinations beyond the heart , 2020, European journal of heart failure.

[4]  Guangwen Long,et al.  Heparin-binding protein measurement improves the prediction of myocardial injury-related cardiogenic shock , 2020, BMC Cardiovascular Disorders.

[5]  F. Fan,et al.  Vacuum-assisted closure vs. bilateral pectoralis major muscle flaps for deep sternal wounds infection , 2020, Journal of thoracic disease.

[6]  N. Ageyama,et al.  Rolipram plus Sivelestat inhibits bone marrow-derived leukocytic lung recruitment after cardiopulmonary bypass in a primate model , 2018, Journal of Artificial Organs.

[7]  Daniel Brodie,et al.  Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment , 2018, JAMA.

[8]  A. de Laat,et al.  Network meta-analysis. , 2017, Journal of oral rehabilitation.

[9]  J. McMurray,et al.  Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction , 2017, Circulation. Heart failure.

[10]  L. Tritapepe,et al.  Stanford-A acute aortic dissection, inflammation, and metalloproteinases: A review , 2015, Annals of medicine.

[11]  S. Forbes,et al.  REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol , 2015, BMJ Open.

[12]  M. Asano,et al.  Sivelestat attenuates lung injury in surgery for congenital heart disease with pulmonary hypertension. , 2013, The Annals of thoracic surgery.

[13]  R. Ohye,et al.  Vasoactive–inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass* , 2010, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[14]  F. Hatori,et al.  A neutrophil elastase inhibitor, sivelestat, improved respiratory and cardiac function in pediatric cardiovascular surgery with cardiopulmonary bypass , 2008, Journal of Anesthesia.

[15]  Y. Okita,et al.  Sivelestat attenuates postoperative pulmonary dysfunction after total arch replacement under deep hypothermia. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[16]  H. Matsuda,et al.  Effect of a Polymorphonuclear Elastase Inhibitor (Sivelestat Sodium) on Acute Lung Injury After Cardiopulmonary Bypass: Findings of a Double-Blind Randomized Study , 2006, Surgery Today.

[17]  O. Shigeta,et al.  Sivelestat reduces inflammatory mediators and preserves neutrophil deformability during simulated extracorporeal circulation. , 2005, The Annals of thoracic surgery.

[18]  A. Arifi,et al.  Pulmonary dysfunction after cardiac surgery. , 2002, Chest.

[19]  Y. Lacasse,et al.  Incidence and predictors of ARDS after cardiac surgery. , 2001, Chest.

[20]  Volkmar Falk,et al.  Humoral Immune Response During Coronary Artery Bypass Grafting: A Comparison of Limited Approach, “Off-Pump” Technique, and Conventional Cardiopulmonary Bypass , 2000, Circulation.

[21]  E. Jones,et al.  Influence of concomitant CABG and urgent/emergent status on mitral valve replacement surgery. , 2000, The Annals of thoracic surgery.

[22]  M. Lindsey,et al.  Interleukin 6 induction in the canine myocardium after cardiopulmonary bypass. , 2000, The Journal of thoracic and cardiovascular surgery.

[23]  K. Taylor,et al.  Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. , 1999, The Annals of thoracic surgery.

[24]  E. Verrier,et al.  The Systemic Inflammatory Response , 1997 .

[25]  Kenichi A. Tanaka,et al.  The inflammatory response to cardiopulmonary bypass , 1997 .

[26]  P. Vouhé,et al.  High-volume, Zero-balanced Hemofiltration to Reduce Delayed Inflammatory Response to Cardiopulmonary Bypass in Children , 1996, Anesthesiology.

[27]  S. Nakamura,et al.  Effects of a specific neutrophil elastase inhibitor (ONO-5046 Na) and neutrophil depletion using a G-1 column on lung reperfusion injury in dogs. , 1996, Transplantation proceedings.

[28]  W. Dreyer,et al.  Neutrophil activation and adhesion molecule expression in a canine model of open heart surgery with cardiopulmonary bypass. , 1995, Cardiovascular research.

[29]  S. Ogoshi,et al.  Complement activation in cardiopulmonary bypass, with special reference to anaphylatoxin production in membrane and bubble oxygenators. , 1988, The Annals of thoracic surgery.

[30]  S Westaby,et al.  Complement and the damaging effects of cardiopulmonary bypass. , 1983, The Journal of thoracic and cardiovascular surgery.

[31]  David Brink,et al.  : A Review of the , 2018 .

[32]  E D Verrier,et al.  Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. , 1997, The Annals of thoracic surgery.